COPLAND ROAD CAPITAL NEW Total Liabilities

Latest as of June 2026: €351.57 Million EUR ≈ $411.03 Million USD

COPLAND ROAD CAPITAL NEW total liabilities. Based on the latest financial reports, COPLAND ROAD CAPITAL NEW (A2P) has total liabilities worth €351.57 Million EUR (≈ $411.03 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of COPLAND ROAD CAPITAL NEW to evaluate the company's liquid asset resilience ratio.

Total Liabilities of COPLAND ROAD CAPITAL NEW (2022–2025)

Total liabilities of COPLAND ROAD CAPITAL NEW from 2022 to 2025. This chart illustrates how COPLAND ROAD CAPITAL NEW's total liabilities have evolved over time, based on quarterly financial data.

COPLAND ROAD CAPITAL NEW Competitors by Total Liabilities

The table below lists competitors of COPLAND ROAD CAPITAL NEW ranked by their total liabilities.

Company Country Total Liabilities
Blumar
SN:BLUMAR
Chile CL$528.09 Million
Sumber Tani Agung Resources Tbk PT
JK:STAA
Indonesia Rp2.82 Trillion
Dodla Dairy Limited
NSE:DODLA
India Rs4.01 Billion
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
Brazil R$35.19 Billion
LiJiang YuLong Tourism Co Ltd
SHE:002033
China CN¥337.82 Million
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
China CN¥35.63 Billion
Janus International Group Inc
NYSE:JBI
USA $749.00 Million
Shanghai Chengdi Constr Co
SHG:603887
China CN¥8.60 Billion

Liability Composition Analysis (2022–2025)

This chart breaks down COPLAND ROAD CAPITAL NEW's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see A2P current and non-current assets.

Liquidity & Leverage Metrics

COPLAND ROAD CAPITAL NEW Total Liabilities Ratios Explained

COPLAND ROAD CAPITAL NEW total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.46 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.64 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how COPLAND ROAD CAPITAL NEW's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for COPLAND ROAD CAPITAL NEW (2022–2025)

The table below shows the annual total liabilities of COPLAND ROAD CAPITAL NEW from 2022 to 2025.

Year Total Liabilities Change
2025-12-31 €265.57 Million
≈ $310.48 Million
+43.37%
2024-12-31 €185.23 Million
≈ $216.56 Million
+11.78%
2023-12-31 €165.71 Million
≈ $193.74 Million
+11.49%
2022-12-31 €148.63 Million
≈ $173.77 Million
--

About COPLAND ROAD CAPITAL NEW

F:A2P Germany Medical Devices
Market Cap
$706.48 Million
€604.29 Million EUR
Market Cap Rank
#10476 Global
#1247 in Germany
Share Price
€70.85
Change (1 day)
-4.19%
52-Week Range
€58.05 - €91.05
All Time High
€91.05
About

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics … Read more